Analysts expect Kymera Therapeutics, Inc. to report revenue of 2.92 M for Q3 26, against a range of 2.78 M to 3.07 M. The most recent reported quarter, Q2 26, came in at 65.00 M, a 88.5% beat against the 34.48 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 3.74 M | 7.39 M | 22.10 M | 11.48 M | 2.76 M | 2.87 M | 34.37 M | 65.00 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 12.00 M | 15.72 M | 10.77 M | 23.25 M | 23.66 M | 14.92 M | 8.15 M | 36.90 M | 3.07 M | 4.22 M | 7.74 M | 8.14 M | 1.49 M | 2.55 M | 13.41 M | 18.67 M | ||||||||||
| Low Estimate | 10.01 M | 14.25 M | 9.97 M | 19.22 M | 21.94 M | 13.32 M | 7.50 M | 32.07 M | 2.78 M | 3.91 M | 6.67 M | 6.76 M | 1.32 M | 2.22 M | 12.23 M | 16.94 M | ||||||||||
| Consensus Estimate | 11.01 M | 14.98 M | 10.37 M | 21.24 M | 22.80 M | 14.12 M | 7.83 M | 34.48 M | 2.92 M | 4.06 M | 7.20 M | 7.45 M | 1.40 M | 2.39 M | 12.82 M | 17.80 M |
Analysts expect Kymera Therapeutics, Inc. to report earnings per share of -1.18 for Q3 26, against a range of -1.28 to -1.08. The most recent reported quarter, Q2 26, came in at -0.62, a 15.1% beat against the -0.73 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.82 | -0.88 | -0.82 | -0.95 | -0.94 | -0.97 | -0.71 | -0.62 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.70 | -0.73 | -0.82 | -0.81 | -0.70 | -0.74 | -0.89 | -0.69 | -1.08 | -1.25 | -1.16 | -1.34 | -1.38 | -1.39 | -1.14 | -1.22 | ||||||||||
| Low Estimate | -0.84 | -0.87 | -0.88 | -0.93 | -0.80 | -0.90 | -0.95 | -0.77 | -1.28 | -1.43 | -1.42 | -1.60 | -1.64 | -1.69 | -1.26 | -1.34 | ||||||||||
| Consensus Estimate | -0.77 | -0.80 | -0.85 | -0.87 | -0.75 | -0.82 | -0.92 | -0.73 | -1.18 | -1.34 | -1.29 | -1.47 | -1.51 | -1.54 | -1.20 | -1.28 |
Pull Wall Street consensus for Kymera Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=KYMR&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "KYMR", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=KYMR&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();